PCSK9 and myocardial infarction: VCU-AlirocRT [52] was another early PCSK9-inhibitor initiation trial, initiating alirocumab treatment at the time of the myocardial infarction (defined as within the first 24 h of presentation) in 20 patients with LDL > 70 mg/dL.